A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

Status:
RECRUITING

Trial end date:
2025-11-24

Target enrollment:

Participant gender:

The purpose of this study is to support the development of remibrutinib dosing recommendations for patients with impaired renal function.

PHASE1

Novartis Pharmaceuticals

remibrutinib